Karima Yacouben

499 total citations
12 papers, 341 citations indexed

About

Karima Yacouben is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Karima Yacouben has authored 12 papers receiving a total of 341 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 5 papers in Genetics and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Karima Yacouben's work include Acute Lymphoblastic Leukemia research (5 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Karima Yacouben is often cited by papers focused on Acute Lymphoblastic Leukemia research (5 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Karima Yacouben collaborates with scholars based in France, Portugal and Belgium. Karima Yacouben's co-authors include André Baruchel, Yves Bertrand, Patrick Lutz, Françoise Mazingue, Frédéric Millot, Joëlle Guilhot, Yves Réguerre, Cécile Verite, Thierry Leblanc and Arnaud Petit and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.

In The Last Decade

Karima Yacouben

12 papers receiving 338 citations

Peers

Karima Yacouben
Jeffrey R. Andolina United States
Maja Bulatović Ćalasan Netherlands
S. K. China
Klaus Rehe Germany
Natalie Sturt United Kingdom
A. Ferster Belgium
J. Shan United States
J.G. Fuzibet France
G Yoffe United States
Gail Abrahamson United Kingdom
Jeffrey R. Andolina United States
Karima Yacouben
Citations per year, relative to Karima Yacouben Karima Yacouben (= 1×) peers Jeffrey R. Andolina

Countries citing papers authored by Karima Yacouben

Since Specialization
Citations

This map shows the geographic impact of Karima Yacouben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karima Yacouben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karima Yacouben more than expected).

Fields of papers citing papers by Karima Yacouben

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karima Yacouben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karima Yacouben. The network helps show where Karima Yacouben may publish in the future.

Co-authorship network of co-authors of Karima Yacouben

This figure shows the co-authorship network connecting the top 25 collaborators of Karima Yacouben. A scholar is included among the top collaborators of Karima Yacouben based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karima Yacouben. Karima Yacouben is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Feghoul, Linda, Sylvie Chevret, Jean‐Hugues Dalle, et al.. (2015). Adenovirus infection and disease in paediatric haematopoietic stem cell transplant patients: clues for antiviral pre-emptive treatment. Clinical Microbiology and Infection. 21(7). 701–709. 49 indexed citations
2.
Millot, Frédéric, Joëlle Guilhot, André Baruchel, et al.. (2014). Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. European Journal of Cancer. 50(18). 3206–3211. 73 indexed citations
3.
Millot, Frédéric, Joëlle Guilhot, André Baruchel, et al.. (2013). Imatinib Has a Negative Impact On Growth In Children With Previously Untreated Chronic Myeloid Leukaemia (CML) In Early Chronic Phase (CP): Results Of The French National Study. Blood. 122(21). 4001–4001. 1 indexed citations
4.
Baulny, Hélène Ogier de, Renata Kozyraki, Sandrine Passemard, et al.. (2012). How can cobalamin injections be spaced in long-term therapy for inborn errors of vitamin B12 absorption?. Molecular Genetics and Metabolism. 107(1-2). 66–71. 15 indexed citations
5.
Millot, Frédéric, André Baruchel, Joëlle Guilhot, et al.. (2011). Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial. Journal of Clinical Oncology. 29(20). 2827–2832. 121 indexed citations
6.
7.
8.
9.
Bader‐Meunier, Brigitte, Nathalie Aladjidi, Fabrice Monpoux, et al.. (2007). Rituximab therapy for childhood Evans syndrome. Haematologica. 92(12). 1691–1694. 41 indexed citations
10.
Aladjidi, Nathalie, Guy Leverger, Alexandre Pariente, et al.. (2006). Épidémiologie des anémies hémolytiques auto-immunes de l'enfant : données de la cohorte française. Archives de Pédiatrie. 13(6). 511–514. 2 indexed citations
11.
Millot, Frédéric, Joëlle Guilhot, Brigitte Nelken, et al.. (2004). Results of a Phase II Trial Testing Interferon Alpha 2b and Cytarabine in Children with Chronic Myelogenous Leukemia.. Blood. 104(11). 1000–1000. 2 indexed citations
12.
Cavé, Hélène, N Philippe, Nathalie Grardel, et al.. (2004). Ras Pathway Activation in Childhood B-Lineage Acute Lymphoblastic Leukemia: Ras, Ptpn11, and Flt3 Mutations.. Blood. 104(11). 166–166. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey R. Andolina Breakdown of academic impact, for papers by Maja Bulatović Ćalasan Breakdown of academic impact, for papers by S. K. Breakdown of academic impact, for papers by Klaus Rehe Breakdown of academic impact, for papers by Natalie Sturt Breakdown of academic impact, for papers by A. Ferster Breakdown of academic impact, for papers by J. Shan Breakdown of academic impact, for papers by J.G. Fuzibet Breakdown of academic impact, for papers by G Yoffe Breakdown of academic impact, for papers by Gail Abrahamson
Rankless by CCL
2026